All In Biotech

Drug Trial Radar · NCT07284589

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Evaluation of Ultralow Dose PET Imaging for Detecting SSTR2 Radiotracer Uptake

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 11, 2025

Primary completion

Apr 30, 2030

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Akiva MintzAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

Conditions

  • Healthy (Controls)
  • Healthy Volunteers
  • Neuroendocrine (NE) Tumors

Interventions

  • 68Ga-DotatateDrug

    Participants will be injected with 68Ga-DOTATATE and imaged for up to 3 hours on a PET scanner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Signal-to-Noise Ratio (SNR)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  2. Contrast-to-Noise Ratio (CNR)Time frame: Time Frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  3. Coefficient of Variation (COV)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  4. Spatial Resolution (Full Width at Half Maximum - FWHM)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  5. Target-to-Background Ratio (TBR)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  6. Qualitative Image Quality Score (Likert Scale)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.
  7. Inter-reader Agreement (Weighted Kappa Statistics)Time frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nuclear Imaging Institute

    Englewood, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.